If you browse condition-focused options, the Type 2 Diabetes collection can help you understand related therapy categories, but treatment choices still require clinical review
2 Majority of patients were treated with standard of care 1,2,n,o Summary of medication at baseline (N=3533) 1,2 Select CV and CKD baseline characteristics (N=3533) 1,2 n At baseline patients in FLOW were receiving standard-of-care background therapy, including a maximum tolerated label dose of a RAAS-blocking agent including an ACE inhibitor or an ARB, unless such treatment was contraindicated or not tolerated
Quick Answer: Semaglutide does not cause clinically significant liver damage in most patients and may improve liver health markers through weight loss effects
This is why a new layer is emerging: A natural lifestyle execution layer that operates continuously in the real world
Patients may experience fewer side effects when using one medication instead of the other
